AI assistant
Lupin Ltd — Capital/Financing Update 2025
May 26, 2025
61031_rns_2025-05-26_1d1e6728-db4c-4faf-8613-143afd533c6f.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [79 x 93] intentionally omitted <==
May 26, 2025
National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 Symbol: LUPIN
BSE Limited
P. J. Towers, Dalal Street, Mumbai Samachar Marg, Mumbai - 400 001
Scrip Code: Equity - 500257
Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’).
Dear Sir/Madam,
We are pleased to enclose a Press Release as regards, the Company has entered into a license and supply agreement with SteinCares, a leading specialty healthcare company in Latin America, for commercialization of Lupin’s biosimilar ranibizumab across Latin America excluding Mexico and Argentina.
The same is for your information and dissemination.
Thanking you,
For LUPIN LIMITED
AMIT KUMAR GUPTA Digitally signed by AMIT KUMAR GUPTA DN: c=IN, st=Maharashtra, 2.5.4.20=f72cf02f52d2a7e595b45b84659bdca28c8f26a939bb35835a169f2a237229a3, postalCode=400705, street=C701 Shivdarshan CHS Ltd Sector16 Plot No5 Navi Mumbai, pseudonym=d3a468d0d03546efabffd2a7cb7aaaae, title=7875, serialNumber=de9bbd80d8994e4be9f0dd2399144eba7e782d70287df6aad1994f0b522fa08a, o=Personal, cn=AMIT KUMAR GUPTA Date: 2025.05.26 10:11:17 +05'30'
AMIT KUMAR GUPTA COMPANY SECRETARY & COMPLIANCE OFFICER (ACS -15754)
Encl: a/a.
LUPIN LIMITED
Registered Office: 3[rd] Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323. Corporate Identity Number: L24100MH1983PLC029442 www.lupin.com
www.lupin.com
Press Release
==> picture [68 x 70] intentionally omitted <==
BSE: 500257 NSE: LUPIN
REUTERS: LUPIN.BO
BLOOMBERG: LPCIN
Lupin and SteinCares Enter into License and Supply Agreement for Ranibizumab in Latin America
Mumbai, Costa Rica, May 26, 2025 : Global Pharma major Lupin Limited (Lupin) today announced that it has entered into a license and supply agreement with SteinCares, a leading specialty healthcare company in Latin America, for commercialization of Lupin’s biosimilar ranibizumab across Latin America excluding Mexico and Argentina.
Under the terms of the agreement, SteinCares will handle all regulatory filings, registrations and commercialization of Ranibizumab in LATAM, while Lupin will be responsible for manufacturing the same.
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A). Its indications encompass the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema Following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Diabetic Retinopathy (DR) and Myopic Choroidal Neovascularization (mCNV).
Dr Cyrus Karkaria, President Biotechnology, Lupin said, “Our partnership with SteinCares underscores our commitment to providing innovative, high-quality healthcare solutions to patients in LATAM. Our intent is to transform the landscape of retinal care in Latin America, ensuring access to advanced therapies that improve the quality of life of patients.”
“This partnership with Lupin strengthens our portfolio and further reinforces SteinCares’ position as a biosimilar powerhouse in Latin America. We have consistently been first to market products from highly regulated markets across several countries in the region. Our presence has translated into significant cost savings for healthcare institutions, driven by decades of experience and a deep understanding of Latin America's healthcare landscape,” said Sebastián Katz, Chief Strategy Officer at SteinCares.
About Lupin
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries - Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.
To know more, visit www.lupin.com or follow us on LinkedIn https://www.linkedin.com/company/lupin
Page 1 of 2
Press Release
==> picture [68 x 70] intentionally omitted <==
BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO BLOOMBERG: LPCIN
For further information or queries please contact:
Rajalakshmi Azariah
Vice President & Global Head – Corporate Communications, Lupin [email protected]
About SteinCares
SteinCares is a leader in the commercialization and distribution of specialty healthcare products in Latin America, including innovative pharmaceuticals, biosimilars and complex generics. With more than 40 years of progressive healthcare experience and operations in over 30 countries in Latin America and the Caribbean, SteinCares serves as a bridge between global pharmaceutical companies and the region’s healthcare providers. The company is deeply committed to creating healthcare opportunities that positively impact the lives of patients and their families in Latin America, with a vision of increasing access to innovative and cost-effective healthcare for patients in the region. For more information, visit http://www.steincares.com/ or follow the company on LinkedIn.
For further information or queries please contact:
Victoria Carrillo
Communications Manager – SteinCares [email protected]
Page 2 of 2